Menu
Back to User profile » Prof. Dr. Junling Li
Papers published by Prof. Dr. Junling Li:
Bevacizumab Combined with Continuation of EGFR-TKIs in NSCLC Beyond Gradual Progression
Xu Z, Teng F, Hao X, Li J, Xing P
Cancer Management and Research 2022, 14:1891-1902
Published Date: 4 June 2022
Efficacy of Osimertinib After Progression of First-Generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor (EGFR-TKI) in EGFR-Mutated Lung Adenocarcinoma: A Real-World Study in Chinese Patients
Xu Z, Hao X, Wang Q, Wang J, Yang K, Wang S, Teng F, Li J, Xing P
Cancer Management and Research 2022, 14:863-873
Published Date: 1 March 2022
Changes and Influential Factors of Chemotherapy Usage for Non-Small Cell Lung Cancer Patients in China: A Multicenter 10-Year (2005–2014) Retrospective Study
Xing PY, Wang SZ, Shi JF, Wang L, Hui ZG, Ren JS, Liu SM, Qiao YL, Dai M, Li JL
Cancer Management and Research 2020, 12:6033-6044
Published Date: 20 July 2020
Real-World Data Of Osimertinib In Patients With Pretreated Non-Small Cell Lung Cancer: A Retrospective Study
Mu Y, Xing P, Hao X, Wang Y, Li J
Cancer Management and Research 2019, 11:9243-9251
Published Date: 30 October 2019
Patient Preferences For Chemotherapy In The Treatment Of Non-Small Cell Lung Cancer: A Multicenter Discrete Choice Experiment (DCE) Study In China
Sun H, Wang H, Xu N, Li J, Shi J, Zhou N, Ni M, Hu X, Chen Y
Patient Preference and Adherence 2019, 13:1701-1709
Published Date: 8 October 2019
Elevated levels of pre-treatment lactate dehydrogenase are an unfavorable predictor factor in patients with EML4-ALK rearrangement non-small cell lung cancer treated with crizotinib
Liang H, Ma D, Xu Y, Zhao J, Chen M, Liu X, Zhong W, Li J, Wang M
Cancer Management and Research 2019, 11:8191-8200
Published Date: 5 September 2019
Second-generation EGFR and ErbB tyrosine kinase inhibitors as first-line treatments for non-small cell lung cancer
Wang S, Li J
OncoTargets and Therapy 2019, 12:6535-6548
Published Date: 15 August 2019
Comparative review of drug–drug interactions with epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small-cell lung cancer
Xu ZY, Li JL
OncoTargets and Therapy 2019, 12:5467-5484
Published Date: 9 July 2019